Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population

Thesis (PhD (Pharmacology))--University of Pretoria, 2021.

Saved in:
Bibliographic Details
Other Authors: Steenkamp, Vanessa
Format: Thesis
Language:English
Published: University of Pretoria 2022
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613480863924224
access_status_str Open Access
author2 Steenkamp, Vanessa
author_browse Steenkamp, Vanessa
author_facet Steenkamp, Vanessa
collection Thesis
dc_rights_str_mv © 2022 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Thesis (PhD (Pharmacology))--University of Pretoria, 2021.
format Thesis
id oai:repository.up.ac.za:2263/84163
institution University of Pretoria (South Africa)
language English
last_indexed 2026-06-10T12:36:49.486Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/84163 Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population Steenkamp, Vanessa bianca.sansom86@gmail.com Jansen van Rensburg, Elizabeth Sansom, Bianca Pharmacogenetics Cancer treatment Adverse drug reactions Single nucleotide polymorphisms Breast Cancer UCTD Thesis (PhD (Pharmacology))--University of Pretoria, 2021. Cancer is a leading cause of morbidity and mortality in both industrialized and developing nations. The true incidence of cancer in unknown in many developing countries, where the burden of the human immunodeficiency virus and tuberculosis take priority. Lung cancer and female breast cancer have the highest number of new cases globally, followed by colorectal cancer, prostate cancer, and stomach cancer. Treatment failure is not uncommon in these types of cancer and are often life threatening. To improve treatment outcome, focus has shifted to incorporate precision medicine. This involves pharmacogenomics which aims to understand how genetic variations influence drug efficacy and toxicity, and how these individual genetic variations affect the manner in which an individual will respond to a specific drug regime or dosage. There are some population groups for which there is limited genetic variation data sets available, such as sub-Saharan African populations. The aim of the study was to establish the prevalence of several single nucleotide polymorphisms (SNPs) that have been highlighted to not only affect the efficacy and toxicity of anti cancer drugs (but other drugs as well) within the South African population of Bantu speakers, bridging a gap in knowledge which could contribute towards improved treatment strategies for cancer treatment. The study protocol was approved by the Ethics Committee of the Faculty of Health Sciences of the University of Pretoria under protocol number 3/2020. A total of 764 DNA samples from four previously recruited cohorts of self-identified black South African Bantu speakers were assessed. The four cohorts included blood bank donors for the study of gene polymorphisms in the general population (Ethics protocol # 73/2006), women with breast cancer for the study of breast cancer genes (Ethics protocol #KCT265), men with prostate cancer for the study of prostate cancer genes (43/2010), and lastly male Tshivenda individuals who were previously enrolled as controls in a study investigating epigenomic changes due to pesticide exposure in a malaria area (Ethics protocol # 43/2003). Sixty genetic polymorphisms, consisting of a single target gene, 13 transport genes and 46 metabolisms genes were investigated. SNPs comprised of missense variants (60%), intron variants (13.3%) and synonymous variants (8.3%). The TaqMan® OpenArray™ genotyping platform was used to genotype the study cohort. The OpenArray™ platform was validated using whole iii genome sequencing. Genotype and allele frequencies for the study population were calculated and compared to data extracted from the 1000 Genomes Project on populations of African and European ancestry to determine the presence of interpopulation variation. Statistical significance (P < 0.05) was determined using both the Chi-square and Fisher exact test. Principle component analysis (PCA) was performed to visualise the variation both between the populations and within the study population. Six polymorphisms showed 100% amplification across all the samples analysed; rs1272155 (CYP2B6), rs11572103 (CYP2C8), rs35599367 (CYP3A4), rs55886062 (DPYD), rs714368 (SLC22A16) and rs1902023 (UGT2B15). The CYP2D6 locus (rs1065852, rs3892097, rs35742686 and rs28371706) had the highest no amplification call rate of all the SNPs investigated. Five variants were fixed within the population, with only homozygotes for the ancestral allele being detected in the study population namely, rs2032582 - C (ABCB1), rs12721655 - A (CYP2B6), rs7900194 – G (CYP2C9), rs55886062 - A and rs67376798 - T (DPYD). Six polymorphisms, rs1065852, rs3892097, rs35742686 and rs28371706 from CYP2D6 family, rs11615 (ERCC1) and rs1042028 (SULT1A1) were found to deviate from HWE (P < 0.05), likely because of the non-specificity of the probes rather than population stratification. The PCA analysis confirmed the presence of both inter- and intra-population diversity, highlighting the importance and need for more large-scale population-based studies of understudied populations. The mechanism of action of the drug and the role that the gene or subsequent enzyme plays in the metabolism of the drug, is the determinant of the risk variant. From the study several of the SNPs were highlighted as important polymorphisms for screening purposes prior to therapy initiation, which is in agreement with previous literature; CBR3 (rs1056892), CYP19A1 (rs4646), CYP2B6*16 (rs28399499), CYP2B6*6 (rs3745274), CYP2C19*17 (rs12248560), CYP2C19*27 (rs7902257), CYP2C8*2 (rs11572103), CYP2D6*17 (rs2837170), CYP3A4*1 (rs4986907), CYP3A4*1B (rs2740574), CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272), CYP3A5*7 (rs41303343), DPYD (rs115232898), SLCO1B3 (rs4149117 and rs7311358), UGT1A6 (rs17863783) and XRCC1 (rs25487). iv Future research should include genomic capacity development in the African continent. Policy developers need to enforce pharmacovigilance reporting, which will enable large pharmaceutical companies to assist in research and funding of projects that will investigate the underlying cause of adverse drug reactions in specific population groups within Africa. South African Medical Research Council Pharmacology PhD (Pharmacology) Unrestricted 2022-02-23T09:18:31Z 2022-02-23T09:18:31Z 2022-04 2021 Thesis * A2022 http://hdl.handle.net/2263/84163 en © 2022 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria
spellingShingle Pharmacogenetics
Cancer treatment
Adverse drug reactions
Single nucleotide polymorphisms
Breast Cancer
UCTD
Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title_full Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title_fullStr Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title_full_unstemmed Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title_short Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population
title_sort prevalence of genetic polymorphisms associated with anti cancer drug efficacy and toxicity in the south african population
topic Pharmacogenetics
Cancer treatment
Adverse drug reactions
Single nucleotide polymorphisms
Breast Cancer
UCTD
url http://hdl.handle.net/2263/84163